Market Overview

UPDATE: Morgan Stanley Downgrades Pacific Biosciences to Underweight, Reiterates $1.50 PT

Related PACB
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Mid-Morning Market Update: Markets Gain; Pacific Ethanol Reports Merger Deal With Aventine Renewable Energy
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% - Tale of the Tape (Zacks)

In a report published Monday, Morgan Stanley downgraded its rating on Pacific Biosciences of California (NASDAQ: PACB) to Underweight, and reiterated its $1.50 price target.

Morgan Stanley noted, “We expected the C2 chemistry to catalyze demand, yet bookings have sharply declined (6 in Q4, 2 in Q1, 1 in Q2). The system has unique traits and mgmt is optimistic noting signs of traction. However, weakening trends and the system's niche commercial appeal, high price, constrained funding and competitive landscape signals a more limited future potential than previously assumed. We cut our forecasts, now estimate 5 new bookings in 2H12 (prior 10) and 9 in '13 (prior 24).”

Pacific Biosciences of California closed on Friday at $2.00.

Latest Ratings for PACB

May 2014JP MorganUpgradesUnderweightNeutral
Aug 2013Piper JaffrayUpgradesUnderweightNeutral
Jul 2012Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for PACB
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Analyst Ratings


Related Articles (PACB)

Around the Web, We're Loving...

Get Benzinga's Newsletters